<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304564/" ref="ordinalpos=1504&amp;ncbi_uid=3893835&amp;link_uid=PMC3304564" image-link="/pmc/articles/PMC3304564/figure/fig02/" class="imagepopup">Figure 2.  From: Therapeutic implications of targeting the PI3Kinase/AKT/mTOR <span class="highlight" style="background-color:">signaling</span> module in melanoma therapy. </a></div><br /><div class="p4l_captionBody">Therapeutic implications of targeting the PI3K/AKT pathway. Schematic depiction of major components of the AKT signaling module and various pharmacological inhibitors (in various sages of clinical testing) that could potentially interfere with the activity of the AKT pathway. These compounds, alone or combined with various other modalities, may improve treatment efficacy.</div></div>